Suchergebnisse - "Ye, Huixia"

PubPharm (14)

1

The indication and treatment outcome predictors of mifepristone treating ectopic pregnancy

enthalten in: Archives of gynecology and obstetrics | 2023

von Tang, P. | Ye, H. | Wang, Y. | +4

2

The indication and treatment outcome predictors of mifepristone treating ectopic pregnancy

enthalten in: Archives of gynecology and obstetrics | 2023

von Tang, P. | Ye, H. | Wang, Y. | +4

3

Rabies vaccine protective agent, rabies vaccine and preparation method of rabies vaccine protective agent

enthalten in: Europäisches Patentamt | 2022

von ZHANG TAO | MAO ZI'AN | TANG YONG | +4

4

OSI-906 Restores The Sensitivity of Ovarian Clear Cell Carcinoma To Cisplatin By Targeting The IGF1R/AKT Pathway

enthalten in: ResearchSquare.com | 2022

von Liu, L. | Liang, C. | Zhuo, C. | +7

5

An Acid Response IR780-Based Targeted Nanoparticle for Intraoperative Near-Infrared Fluorescence Imaging of Ovarian Cancer

enthalten in: International journal of nanomedicine | 2022

von Song, J. | Ye, H. | Jiang, S. | +2

6

OSI-906 restores the sensitivity of ovarian clear cell carcinoma to cisplatin by targeting the IGF1R/AKT pathway

enthalten in: Medical oncology (Northwood, London, England) | 2022

von Liu, L. | Liang, C. | Zhuo, C. | +7

7

OSI-906 restores the sensitivity of ovarian clear cell carcinoma to cisplatin by targeting the IGF1R/AKT pathway

enthalten in: Medical oncology | 2022

von Liu, L. | Liang, C. | Zhuo, C. | +7

8

OSI-906 restores the sensitivity of ovarian clear cell carcinoma to cisplatin by targeting the IGF1R/AKT pathway

enthalten in: Medical oncology | 2022

von Liu, L. | Liang, C. | Zhuo, C. | +7

9

OSI-906 restores the sensitivity of ovarian clear cell carcinoma to cisplatin by targeting the IGF1R/AKT pathway

enthalten in: Medical oncology | 2022

von Liu, L. | Liang, C. | Zhuo, C. | +7

10

Screening History and Diagnostic Characteristics of Cervical Adenocarcinoma: a Retrospective Study

enthalten in: ResearchSquare.com | 2021

von Li, J. | Ye, M. | Ye, H. | +3